TORRANCE, Calif., Nov. 14, 2022 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of operations and financial condition as of and for the three and nine months ended September30, 2022 and provided a business update.
Recent Highlights
“We enjoyed a third straight substantial increase in quarterly net revenue on the strength of increased sales in the Middle East North Africa (MENA) region. Sell-through by our domestic distributors also increased, although our domestic sales were relatively flat compared to the second quarter due to a large bulk order as the second quarter was ending. We anticipate a further increase in net revenue in Q4 as we complete the first bulk production of product packaging specific to the MENA region,” stated Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive…
